The Medicines Company (MDCO)

Company Description

The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in cardiovascular events such PTCA and stenting; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent that is Phase III clinical trial for the prevention of platelet activation; Oritavancin, an investigational intravenous antibiotic, which is in Phase III clinical trials for the treatment of acute bacterial infections; and IONSYS, a pre-registration stage product for the short-term management of acute postoperative pain. Products under development include MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of coronary events in patients with ACS; and ALN-PCS, a development program for the treatment of hypercholesterolemia. In addition, it offers acute care generic products for use in the cardiovascular, neurocritical care, and serious infection therapeutic areas; and promotes BRILINTA, an oral tablet antiplatelet medicine. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc. and AstraZeneca LP.

 

 

COMPANY ADDRESS
The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 U.S.A
United States

COMPANY PHONE
973-290-6000
Toll-free: 800-388-1183

COMPANY WEBSITE



Get BioInvest's perspective on the Medicines Company's CEO


Latest Company News

The Medicines Company Announces FDA Filing Acceptance of New Drug Application ... Business Wire (press release) - Feb 21, 2017 PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Company's new drug application (NDA) filing for Carbavance® ... Carbavance Gets Priority Review for Complicated UTI - Monthly Prescribing Reference (registration) [...]
Tue, Feb 21, 2017 12:15:00 PM, Continue reading at the source
Lookout for Price Target? Texas Roadhouse, Inc. (TXRH), The Medicines Company ... StockNewsJournal - Feb 20, 2017 The Medicines Company (NASDAQ:MDCO), at its latest closing price of $53.40, it has a price-to-book ratio of 4.95, compared to an industry average at 4.03. [...]
Mon, Feb 20, 2017 7:30:00 PM, Continue reading at the source
The Medicines Company (MDCO) Breaks into New 52-Week High on February 17 Session Equities.com - Feb 17, 2017 Shares of The Medicines Company (MDCO) broke into a new 52-week high yesterday, hitting a peak of $53.92. Shares closed at $53.40 after opening at $52.18 for a move of 1.14%. The Brokerages Set The Medicines Company (MDCO) Target Price at the $48.29 - DailyQuint Street Target Update on The Medicines Company (NASDAQ:MDCO) - Rockville Register [...]
Fri, Feb 17, 2017 10:30:00 PM, Continue reading at the source
The Medicines Company to Announce Fourth-Quarter and Full-Year 2016 Financial ... Yahoo Finance - Feb 17, 2017 The Medicines Company is a biopharmaceutical company driven by an overriding purpose - to save lives, alleviate suffering and contribute to the economics of healthcare. [...]
Fri, Feb 17, 2017 12:05:00 PM, Continue reading at the source
The Medicines Company (MDCO) Breaks into New 52-Week High on February 15 Session Equities.com - Feb 15, 2017 Shares of The Medicines Company (MDCO) broke into a new 52-week high yesterday, hitting a peak of $52.66. Shares closed at $52.56 after opening at $51.36 for a move of 2.02%. [...]
Wed, Feb 15, 2017 10:30:00 PM, Continue reading at the source
The Medicines Company (MDCO) Breaks into New 52-Week High on February 14 Session Equities.com - Feb 14, 2017 Shares of The Medicines Company (MDCO) broke into a new 52-week high yesterday, hitting a peak of $51.54. Shares closed at $51.52 after opening at $50.51 for a move of 1.72%. The Medicines Company (NASDAQ:MDCO) Surged 1.72% - TopChronicle [...]
Tue, Feb 14, 2017 10:30:00 PM, Continue reading at the source
The Medicines Company (MDCO) Breaks into New 52-Week High on February 09 Session Equities.com - Feb 9, 2017 Shares of The Medicines Company (MDCO) broke into a new 52-week high yesterday, hitting a peak of $49.09. Shares closed at $48.75 after opening at $47.26 for a move of 3.22%. The Medicines Company (NASDAQ:MDCO) Insider Trading Update - The Newburgh Press The Medicines Company (NASDAQ:MDCO) added 25.2 percent in its Stock After ... - FactsReporter [...]
Thu, Feb 09, 2017 10:30:00 PM, Continue reading at the source
The Medicines Company: New Entrant In Cholesterol Drug Wars? Seeking Alpha - Feb 6, 2017 A mid-cap biotech concern called The Medicines Group saw a 20% jump in its price Friday on the cardiovascular study results from Amgen's new cholesterol drug Repatha. [...]
Mon, Feb 06, 2017 7:41:00 PM, Continue reading at the source
Why The Medicines Company Rocketed Higher Today Motley Fool - Feb 3, 2017 The Medicines Company (NASDAQ:MDCO) shot up 21% today after competitor Amgen (NASDAQ:AMGN) announced data from its FOURIER clinical trial. FOURIER Data Good For Amgen (AMGN), Better for The Medicines Company (MDCO ... - StreetInsider.com Amgen's LDL-Buster Boosts The Medicines Co., But Regeneron Slides - Investor's Business Daily [...]
Fri, Feb 03, 2017 9:33:00 PM, Continue reading at the source
The Medicines Company (MDCO) Moves Higher on Volume Spike for February 01 Equities.com - Feb 1, 2017 The Medicines Company (MDCO) traded on unusually high volume on Feb. 01, as the stock gained 3.33% to close at $37.25. On the day, The Medicines Company saw 1.63 million shares trade hands on 7,732 trades. Considering that the stock averages only ... The Virtus ETF Advisers LLC Boosts Stake in The Medicines Co. (MDCO) - DailyQuint Broker Outlook For The Week Ahead The Medicines Company (NASDAQ:MDCO) - Fiscal Standard [...]
Wed, Feb 01, 2017 10:30:00 PM, Continue reading at the source